Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Two Pre-clinical Short Interfering RNA (siRNA) Molecules Targeting Human HSD17β13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Monday, October 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the development of two pre-clinical short interfering RNA (siRNA) molecules aimed at targeting human HSD17B13. These molecules are being investigated for their potential in treating metabolic dysfunction-associated steatohepatitis (MASH). This research represents a significant step forward in addressing metabolic diseases.
Price reaction · baseline $7.5 (2024-10-07 close) · hit after-hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Development of two novel siRNA molecules.
  • Targeting HSD17B13 shows potential for treating metabolic diseases.
  • Focus on metabolic dysfunction-associated steatohepatitis (MASH).

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What are the new siRNA molecules targeting?

The siRNA molecules are targeting human HSD17B13.

What condition are the siRNA molecules aimed to treat?

They are aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

What stage is the development of these siRNA molecules?

The development is currently in the pre-clinical stage.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare siRNA HSD17B13 metabolic dysfunction steatohepatitis
Last updated: Oct 7, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →